Drugs Made In Am Stock Price, News & Analysis
Company Description
Drugs Made In Am (NASDAQ: DMIIR) is a publicly traded company in the Blank Checks sector.
DMIIR stock has declined 45.0% over the past year. Shares last traded at $0.0900.
On a trailing twelve-month basis, Drugs Made In Am reported net income of $4.2M.
This page provides a comprehensive overview of DMIIR stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Drugs Made In Am (DMIIR) stock last traded at $0.0900, down 2.22% from the previous close. Over the past 12 months, the stock has lost 45.0%.
Latest News
SEC Filings
Drugs Made In Am has filed 10 recent SEC filings, including 6 Form 8-K, 2 Form 10-Q, 2 Form 10-K. The most recent filing was submitted on May 14, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all DMIIR SEC filings →
Financial Highlights
operating income reached -$488K, and net income was $4.2M. The company generated -$1.0M in operating cash flow. With a current ratio of 0.09, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Short interest in Drugs Made In Am (DMIIR) currently stands at 19.9 thousand shares, down 15.4% from the previous reporting period. Over the past 12 months, short interest has increased by 4870%.
Days to Cover History
Days to cover for Drugs Made In Am (DMIIR) currently stands at 3.8 days, down 62.9% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The days to cover has increased 278% over the past year, indicating improving liquidity conditions. The ratio has shown significant volatility over the period, ranging from 1.0 to 10.2 days.
DMIIR Company Profile & Sector Positioning
Drugs Made In Am (DMIIR) operates in the Blank Checks sector and is listed on the NASDAQ.